# NAD+ Injections: What the Evidence Shows

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-05

Canonical page: https://glpwatchdog.org/research/nad-injections-what-the-evidence-shows

> A 2026 systematic review screened 113 studies and found no outcomes trials of injected NAD+ for anti-aging or wellness. With sermorelin, it is one of the two most common add-ons in our register: 142 of 560 sellers offered NAD+ and 147 offered sermorelin at the August 2026 count.

## Key points

- A 2026 PRISMA review of 113 studies found ZERO outcomes trials of injected NAD+.
- The trials that exist test ORAL precursors (NR, NMN), a different molecule by a different route.
- Oral precursors reliably raise NAD+ levels; effects on how people feel or function are often null.
- 142 of 560 sellers in our register offered it at the August 2026 count. Ten published what it costs.

NAD+ and sermorelin are the two things most often sold beside a GLP-1, often under the heading of [peptide therapy](https://glpwatchdog.org/research/what-is-peptide-therapy), although NAD+ is not a peptide. In our own register at its August 2026 count, **142 of 560 sellers** listed NAD+ and 147 listed sermorelin, and NAD+ is nearly always sold as an injection or a drip. A systematic review published in 2026 screened the entire literature and found **no outcomes trials of injected NAD+ at all** for the purposes it is sold for.[1] The evidence people cite is real, but it is about a different product.

## Oral precursors and injected NAD+ are not the same question

Almost every human trial in this field tests an *oral precursor*, nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), taken as a capsule.[4] What clinics sell is NAD+ itself, pushed into a vein or a muscle. Those are different molecules by a different route, and the trial record does not carry across from one to the other. The two are compared directly in [NAD+ vs NMN](https://glpwatchdog.org/research/nad-plus-vs-nmn).

The 2026 review is unusually explicit about it. Working to PRISMA methodology across studies published between January 2010 and October 2025, the authors identified 113 eligible studies: 33 human intervention studies, 28 of them randomized, and 80 in rodents. On the injected form, not one eligible outcomes trial tested NAD+ itself, given intravenously or intramuscularly, for an anti-aging or wellness indication.[1]

> One nonrandomized intravenous NMN study met inclusion criteria and primarily contributed short-term safety and biomarker information. An intravenous NAD+ pharmacokinetic pilot lacking eligible clinical outcomes was identified as contextual evidence only.
>
> — Gallagher and Emmanuel, Ageing Research Reviews, 2026

> **An absence of trials is not proof that something fails.** It means nobody has run the test, so nobody, including the clinic charging you, knows the answer. That is a different claim from “it does not work”. What it does mean is that any confident statement of benefit from an injected NAD+ product is not resting on evidence.

## What the oral evidence found

Here the picture splits cleanly in two.

- **Target engagement: consistent.** Oral NR and NMN [reliably raise NAD-related metabolites](https://glpwatchdog.org/research/nad-supplements-which-raise-levels) in blood and in cells, and were generally well tolerated over weeks to months.[1] The supplement does the biochemical thing it claims to do.
- **Outcomes: heterogeneous, and often null.** Effects on functional, metabolic, vascular and other healthspan-relevant endpoints were inconsistent and frequently absent or specific to a single endpoint.[1]

The gap between those two findings is the story of this field. Raising a molecule in the blood is not the same as changing how someone feels or functions, and NAD+ has become a case study in the difference. A 2025 review in Nature Metabolism covers the same terrain from the precursor side, setting out the clinical evidence alongside the methodological problems that make it hard to read.[2]

There are real positives in the record and they deserve naming. A 2021 randomized trial published in Science found that, in women with prediabetes, NMN improved insulin sensitivity in muscle.[3] That is a specific finding, in a specific population, on a specific endpoint, and it should be described that way, not the way it is usually sold. The full trial-by-trial record on aging markers is in [NAD+ and longevity: what the trials show](https://glpwatchdog.org/research/nad-and-longevity-what-the-trials-show).

## What this looks like on a seller's site

NAD+ occupies a particular slot in the telehealth catalog. It is rarely the thing you arrived for; it appears once you are already buying something else, usually framed around energy, focus, recovery or aging. Of the 142 sellers in our register that offer it, only ten publish what it costs.

A published price is the easiest disclosure a seller can make, and the overwhelming majority of these sellers do not make it for this product. [Clover Meds](https://glpwatchdog.org/reviews/clover-meds) is an exception: its NAD+ page lists $198 for a 4-week supply of twelve 80 mg subcutaneous injections. [IonicMD](https://glpwatchdog.org/reviews/ionicmd) prints its price as well, $199 per 4 weeks for a twice-weekly NAD+ injection. [Stone Health](https://glpwatchdog.org/reviews/stone-health) charges $229 every 4 weeks and offers NAD+ as an injection, a nasal spray or a tablet at that one price. [Sculpt Rx](https://glpwatchdog.org/reviews/sculpt-rx) is more typical, selling NAD+ injections beside its GLP-1s with no price on the site.The same pattern holds for [glutathione](https://glpwatchdog.org/research/glutathione-what-the-evidence-shows), the third most common add-on, which only a handful of sellers price. Our [seller comparison](https://glpwatchdog.org/compare) shows what each one discloses, and [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded) covers the harder regulatory line that some peptide menus cross. Another metabolic add-on sold online, [5-amino-1MQ](https://glpwatchdog.org/research/5-amino-1mq-what-the-evidence-shows), rests on mouse studies alone. [L-carnitine shots](https://glpwatchdog.org/research/l-carnitine-injections-evidence) borrow their case from oral supplement trials.

Look at a few catalogs and the slot is easy to spot. [Mondae](https://glpwatchdog.org/reviews/mondae) sells NAD+ injections beside its compounded GLP-1s, along with sermorelin and glutathione, and [LifespanningRx](https://glpwatchdog.org/reviews/lifespanningrx) folds NAD+ into a wider peptide and longevity program that has a weight-loss arm. [Rebody Health](https://glpwatchdog.org/reviews/rebody-health) has gone further: it no longer sells GLP-1 medication at all, and NAD+ is one of the prescription peptides it now sells, in forms that include a spray and a cream. [Ivim Health](https://glpwatchdog.org/reviews/ivim-health) also lists NAD+ and sermorelin next to its compounded semaglutide and tirzepatide.

Elsewhere it is a side line. [Glam Health](https://glpwatchdog.org/reviews/glam-health) offers NAD+ wellness plans next to its GLP-1 cards. [MangoRx](https://glpwatchdog.org/reviews/mangorx), [Sunlight](https://glpwatchdog.org/reviews/sunlight) and [Obu Health](https://glpwatchdog.org/reviews/obu-health) each list NAD+ beside a GLP-1, and so do [YourEra](https://glpwatchdog.org/reviews/yourera), [MadeMed](https://glpwatchdog.org/reviews/mademed) and [TelePeptide](https://glpwatchdog.org/reviews/telepeptide). [Ora Medical Clinic](https://glpwatchdog.org/reviews/ora-medical-clinic) lists NAD+ among its add-on treatments with metformin, sermorelin and vitamin B12, without prices. [Limitless Male](https://glpwatchdog.org/reviews/limitless-male), an in-person men’s clinic chain, offers compounded NAD+ by injection and also publishes no price. At [Restore Hyper Wellness](https://glpwatchdog.org/reviews/restore-hyper-wellness), a franchise of studios, NAD+ is given in person as an IV drip or an intramuscular shot. If one of them offers it to you, ask for the cost in writing and what the prescriber expects it to do, because the trials above do not answer that for the injected form. [Ironvale RX](https://glpwatchdog.org/reviews/ironvale-rx) does not sell NAD+ on its own at all: it is a $100-a-month add-on to a GLP-1 bundle, paired with ondansetron if prescribed.

> If you are taking a GLP-1 and feeling flat, the more likely explanations are ones with evidence behind them and no add-on purchase attached: eating too little, losing muscle, or a nutrient gap opened up by a much smaller appetite. Our articles on [fatigue on a GLP-1](https://glpwatchdog.org/research/glp1-fatigue-what-causes-it) and [eating too little](https://glpwatchdog.org/research/eating-too-little-on-a-glp1) cover those first.

## Where the evidence stands

[NAD+ biology](https://glpwatchdog.org/research/what-is-nad-plus) is a serious research field, not a fraud. The usual premise, that NAD+ falls with age, is less settled in people than sellers imply: a 2026 study across seven human cohorts found whole-blood NAD+ stable with age, which does not settle what happens inside tissues.[6] Augmenting it does measurable things, and rodent work has repeatedly shown improvements across metabolic, mitochondrial, inflammatory and functional measures.[1] Reviews of NAD across clinical conditions continue to find the safety picture broadly reassuring.[5]

What has not happened is the step from that to a demonstrated benefit in people, for the injected product, at the price a clinic charges. The 2026 review’s own conclusion is that clinical effectiveness for anti-aging or wellness outcomes remains inconclusive, and that larger randomized trials with longer follow-up are needed, “particularly for parenteral approaches.”[1] Those are the ones being sold. A separate 2026 narrative review of IV NAD+ called the evidence preliminary and not enough to support routine clinical or wellness use.[7]

## Frequently asked questions

### Do NAD+ injections work?

Nobody knows, because the trials have not been done. A 2026 PRISMA-guided systematic review screening studies from 2010 to 2025 turned up zero eligible outcomes trials of NAD+ given intravenously or intramuscularly for anti-aging or wellness. That is an absence of evidence rather than evidence of failure, but it means confident claims of benefit are not resting on trials.

### What about oral NAD+ boosters like NR and NMN?

Those have been studied much more, and the results split. They reliably raise NAD-related metabolites and are generally well tolerated over weeks to months, but their effects on functional, metabolic and vascular outcomes are inconsistent and often null. One exception: a 2021 randomized trial in Science found that muscle insulin sensitivity improved in women with prediabetes.

### Is NAD+ dangerous?

The safety signal in the published work is broadly reassuring, with oral precursors generally well tolerated across trials lasting weeks to months. The open question in this field is effectiveness, not safety, though the injected form has far less trial exposure behind it than the oral one.

### Why do so many GLP-1 sellers offer it?

It is one of the two most common add-ons in our register. At its August 2026 count, 142 of the 560 sellers we track listed NAD+, and 147 listed sermorelin. It is rarely the reason someone arrives at a site; it appears alongside something else. Only ten of those 142 publish what it costs.

### I'm exhausted on my GLP-1. Would NAD+ help?

There is no trial evidence that it would, and there are more likely explanations worth ruling out first: eating too little, muscle loss, or a nutrient gap created by a much smaller appetite. Those have evidence behind them and no add-on attached.

## References

1. Gallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026. PMID: 41655607. https://pubmed.ncbi.nlm.nih.gov/41655607/
2. Vinten KT, Trętowicz MM, Coskun E, et al. NAD(+) precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. 2025. PMID: 41083806. https://pubmed.ncbi.nlm.nih.gov/41083806/
3. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID: 33888596. https://pubmed.ncbi.nlm.nih.gov/33888596/
4. Freeberg KA, Udovich CC, Martens CR, et al. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. The Journals of Gerontology: Series A. 2023. PMID: 37068054. https://pubmed.ncbi.nlm.nih.gov/37068054/
5. Gindri IM, Ferrari G, Pinto LPS, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. American Journal of Physiology: Endocrinology and Metabolism. 2024. PMID: 37971292. https://pubmed.ncbi.nlm.nih.gov/37971292/
6. Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD(+) levels do not vary with age or lifestyle interventions. Nature Metabolism. 2026. PMID: 42135539. https://pubmed.ncbi.nlm.nih.gov/42135539/
7. Alangari A, Arif J, Al Qureshah F, Alkhodairy F. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Frontiers in Aging. 2026. PMID: 42787547. https://pubmed.ncbi.nlm.nih.gov/42787547/

---

Cite as: GLP Watchdog, Nora Bissett, "NAD+ Injections: What the Evidence Shows", published 2026-08-19, updated 2026-11-05. https://glpwatchdog.org/research/nad-injections-what-the-evidence-shows

Canonical HTML page: https://glpwatchdog.org/research/nad-injections-what-the-evidence-shows

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
